Sunday, November 20, 2022

MARKSANS PHARMA BUY करो और HOLD करो..!

In the last write up we caught bank stock [Bank Of Maharashtra] and that doing well as per our expectations. Now we have found one more stock from the pharma sector which is Marksans Pharma Ltd. Marksans Pharma is engaged in the business of formulation of pharmaceutical products. Their key focus areas lie in the OTC & prescription drugs that have wide-ranging applications across fields like Oncology, Gastroenterology, Antidiabetic, Antibiotics, Cardiovascular, Pain Management, and Gynaecology, among others. UK & US are their largest customers contributing 42% & 43% respectively out of 25+ countries. The company aims to reach 2000 Cr. revenue in the next few years.

Chart Outlook: After the first lockdown stock price has risen from 10 and touched 98 i.e. almost 10 times. Again stock price come down to 40 and gave a reversal signal on the major time frames chart. On the monthly chart stock price is making Inverse H&S that is the trend change signal. On the weekly chart, the price has given a breakout to its down trendline. So we are expecting 20-30% up moves from the current levels for the medium to long term.




































Fundamental Outlook:

1.      The company is almost debt free.

2.      Yearly net profits are increasing.

3.      The company is focusing on business expansion.

4.      It has a good cash flow.

5.      FIIs and DIIs are gradually increasing their holdings.

6.      Return on equity is around 20%.

If look at the product of the company then those are the demanding. Based on these all parameters we are bullish on the stock.

Telegram: https://t.me/Intraday_King

-------------------------------------------------------------------------------------------------------------------

Disclaimer: The contents produced here are purely for educational purposes. They should not be construed as buy/sell recommendations. I am not a SEBI registered Analyst or Investment Advisor. Readers are advised to consult their Investment advisor before taking any decisions based on the above write-up.


No comments:

Post a Comment